RE:Higher please, as I too wait for Steve This was back in 2018
GW Pharmaceuticals could be on track to become the first company ever to win FDA approval for a plant-based cannabinoid drug. An FDA approval decision on Epidiolex in treating Dravet syndrome and Lennox-Gastaut syndrome (LGS), both rare forms of epilepsy, is expected by June 27, 2018.
The active ingredient in Epidiolex is cannabidiol (CBD), which is already available in states that allow the use of medical marijuana. However, GW Pharmaceuticals' drug uses a very high therapeutic dosage compared to other CBD products. Only three drugs based on marijuana have been approved by the FDA so far. However, all three of these drugs use synthetic versions of cannabinoids. Epidiolex, on the other hand, is made from CBD extracted from marijuana plants.
Expectations are high for Epidiolex. GW Pharmaceuticals reported great results from several phase 3 clinical studies of the drug. Market research firm EvaluatePharma projected that Epidiolex could be one of the 10 biggest new products launched in 2018, and that the drug could generate sales approaching $1 billion by 2022.